Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy

PURPOSE: To report the efficacy and safety of brolucizumab in the treatment of refractory serous pigment epithelial detachment (PED) secondary to polypoidal choroidal vasculopathy (PCV). METHODS: Twenty-six eyes of 26 patients were included. Intravitreal brolucizumab 6.0 mg was administered, followe...

Descripción completa

Detalles Bibliográficos
Autores principales: Nam, Seung Wan, Byun, Zeeyoon, Ham, Don-Il, Kong, Mingui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749193/
https://www.ncbi.nlm.nih.gov/pubmed/36514022
http://dx.doi.org/10.1186/s12886-022-02711-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9749193/
https://www.ncbi.nlm.nih.gov/pubmed/36514022
http://dx.doi.org/10.1186/s12886-022-02711-5

Ejemplares similares